However, with the more recently introduced SGLT2 inhibitors and GLP-1 receptor agonists having shown impressive cardiovascular risk reduction in addition to glycemic control efficacy, these newer agents may also be considered as first-line therapies in patients with pre-existing cardiovascular or renal disease (Garber 2020)
These are liquid extracts that can be taken orally or added to food and drinks
We can finally stop worrying about SGLT2 inhibitors and acute kidney injury
The underlying molecular mechanisms involve direct ROS-induced oxidative damage to neuronal lipids, proteins and DNA [331], as well as ROS-mediated oxidative modifications that crucially promote the aberrant aggregation of toxic proteins [332]
Based on the limited research available we can see that documented BPC-157 side effects include [4]: Injection site injuries (redness, scarring, etc) Nausea Fatigue Sweating Light-headedness Research into BPC-157s long-term side effects is lacking, warranting further investigation